BASEL, Switzerland,
Oct. 4 /PRNewswire-FirstCall/ -
Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) Pursuant to
the company's press release issued the 30th of September 2010, the following is a brief review
and explanation of the earlier statements concerning the first of
many Neuro-Biotech's licensed products, "SymPath(R) blood
test".
For a better understanding, an "in vitro" blood test is
described as, a non evasive test, whereas the testing, as in the
case of SymPath(R), is performed on a small amount of the patient's
blood. To date the SymPath(R) blood test has been tested on several
thousand of patients whose results illustrate a success rate
accuracy of 98.8%. The testing audits have been rigorously
documented and have met every industry standard.
SymPath(R) is an indispensable tool with unprecedented results.
Medical practitioners have long been waiting for a similar test to
accurately and quantifiably diagnose those symptoms amongst
patients as, depression and stress related disorders. What does
this mean for physicians?
Firstly, SymPath(R) assists the medical practitioner in
diagnosing patients, based on quantitative measurement, as precise
as current cholesterol tests. SymPath(R) allows the medical
practitioner to determine with accuracy the severity level of the
patient's anxiety or depressive state. The medical practitioner
will now be able to state, based on an objective quantified
measure, using this test, rather than subjectively determining the
diagnosis, as is currently performed.
Furthermore SymPath(R) will eliminate the costly and highly
inefficient trial and errors currently performed by physicians in
prescribing their recommended remedy, which can waste time and
further cause harm for both patients and physicians. For instance,
patients suffering from depression or stress related disorders will
now properly diagnosed immediately following the testing through
Neuro-Biotech's SymPath(R) test.
No more guessing, medical practitioners will now be able to not
only obtain accurate results, moreover, they will be able to
properly diagnose their patients and prescribe the appropriate
therapeutic approach and continued follow up with the patients.
SymPath(R) testing and its look into the intricate workings of
the diverse mechanisms of the brain shall considerably reduce a
patient's burden during these already difficult times, furnishing
physicians with a medically proven test, allowing for precise,
effective and speedy diagnosis.
Equally, the SymPath(R) test will also allow major employers and
a multitude of organizations within the health industry such as
insurance companies, health providers, health establishments and
governments in their efforts in reducing inefficiencies and most
importantly cost.
To obtain the background scientific documentation concerning
SymPath(R), the company shall provide on its website within days
and weeks to come, several reports, findings and other such
documents.
For more information, do not hesitate to contact us by writing
to info@neuro-agora.com and your request will be transferred to the
appropriate persons and we will get back to you as soon as
possible.
Contact:
Neuro-Biotech Corp.
Dr Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
Forward Looking Statements
This release contains statements that are made pursuant to the
Safe Harbor Provisions of the Private Securities Litigation Act of
1995. Certain statements in this press release may contain words
such as "anticipates," "believes," "could," "expects," "intends,"
"may," "projects," "targets" and other similar language that is
considered forward-looking statements. These forward-looking
statements are subject to certain risks and uncertainties and
persons reading this release are cautioned that such statements are
only predictions, and that the Company's actual future results or
performance may be materially different. The Company disclaims any
intention or obligation to update or revise forward-looking
information, whether as a result of new information, future events,
or otherwise, could cause the company's actual results to differ
materially from those indicated in any forward-looking
statements.
SOURCE Neuro-Biotech Corp.
Copyright t. 4 PR Newswire